Cited by 143Liver Disease and TransplantationOrgan Transplantation Techniques and OutcomesLiver Disease Diagnosis and Treatment

Evaluation of the increase in model for end-stage liver disease (ΔMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child–Turcotte–Pugh score

Huo, Teh-Ia, Wu, Jaw-Ching, Lin, Han-Chieh, Lee, Fa-Yauh, Hou, Ming-Chih, Lee, Pui-Ching, Chang, Full-Young, Lee, Shou-Dong·2005·Journal of Hepatology

Abstract

Background/aims The model for end-stage liver disease (MELD) has been used to prioritize cirrhotic patients awaiting liver transplantation. The change in MELD score over time (DeltaMELD) may have additional prognostic value. We investigated the ability of DeltaMELD to predict the outcome of advanced cirrhosis and prospectively assessed the factors associated with increasing DeltaMELD. Methods Risk factors were determined in 58 prospectively followed-up patients. The predictive power of DeltaMELD, initial MELD and Child-Turcotte-Pugh (CTP) score was compared by using c-statistic in 351 patients. Results Ascites (P=0.020) and hepatic encephalopathy (P=0.023) were significantly associated with increasing MELD score at 3 months. The area under receiver operating characteristic (ROC) curve for DeltaMELD/month was 0.779 compared with 0.718 for MELD (P=0.130) and 0.528 for CTP score (P<0.001) at 6 months; the area was 0.822, 0.744 and 0.528, respectively (P=0.018 and <0.001, respectively) at 12 months. DeltaMELD/month >2.5 was the only significant prognostic predictor at 6 (odds ratio: 9.8, P<0.001) and 12 months (odds ratio: 16.3, P<0.001) in multivariate logistic analysis. Conclusions Increasing MELD score is associated with the onset of ascites and encephalopathy. DeltaMELD is superior to initial MELD and CTP scores to predict intermediate term outcome in patients with advanced cirrhosis.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2005.01.019

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The field has recognised that the MELD score is not the most optimal endpoint for evaluating therapeutic efficacy in trials targeting fibrosis progression and resolution.

    “Since the trial was designed and initiated, the field has recognised that the MELD score is not the most optimal endpoint for evaluating therapeutic efficacy in trials targeting fibrosis progression and resolution (177, 178)”

    From Targeting macrophages in liver fibrosis (2026) · cites this paper as [177]

  • The use of the MELD score as the primary endpoint is an important design limitation of the MATCH study.

    “An important design limitation of the MATCH study concerns the use of the MELD score as the primary endpoint (177).”

    From Targeting macrophages in liver fibrosis (2026) · cites this paper as [177]

Cited by

Sorted by citations

Authors
Huo, T.-I., Wu, J.-C., Lin, H.-C., Lee, F.-Y., Hou, M.-C., Lee, P.-C., Chang, F.-Y., & Lee, S.-D.
Affiliations
Taipei Veterans General Hospital (TW)
Corresponding author
Huo, Teh-Ia
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2005-06
Volume
42
Issue
6
Pages
826-832
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2054857478
Cited by
143
References
0
Citations by year
2026: 3 · 2025: 5 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 9 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 9
FWCI
6.42
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hepatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Science Council
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
Model for End-Stage Liver Disease, advanced cirrhosis, outcome prediction, Child-Pugh score, ascites, hepatic encephalopathy, liver transplantation, risk factors
MeSH terms
Aged, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Predictive Value of Tests, Prognosis, Prospective Studies, Risk Factors, Severity of Illness Index, Proportional Hazards Models, Liver Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review